دورية أكاديمية
Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors.
| العنوان: | Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors. |
|---|---|
| المؤلفون: | Li Q; College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Oduro PK; Research Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine & State Key Laboratory of Component-Based Chinese Medicine, Ministry of Education, Tianjin, China., Guo R; Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Li R; Research Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine & State Key Laboratory of Component-Based Chinese Medicine, Ministry of Education, Tianjin, China., Leng L; Research Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine & State Key Laboratory of Component-Based Chinese Medicine, Ministry of Education, Tianjin, China., Kong X; College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China., Wang Q; Research Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine & State Key Laboratory of Component-Based Chinese Medicine, Ministry of Education, Tianjin, China., Yang L; Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.; School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China. |
| المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2022 Jun 03; Vol. 12, pp. 921534. Date of Electronic Publication: 2022 Jun 03 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
| مواضيع طبية MeSH: | Gastrointestinal Neoplasms*/etiology , Gastrointestinal Neoplasms*/therapy , Neoplasms*/etiology , Oncolytic Virotherapy*/adverse effects , Oncolytic Virotherapy*/methods , Oncolytic Viruses*, Humans ; Immunologic Factors ; Immunotherapy/methods |
| مستخلص: | Oncolytic virus therapy has advanced rapidly in recent years. Natural or transgenic viruses can target tumor cells and inhibit tumor growth and metastasis in various ways without interfering with normal cell and tissue function. Oncolytic viruses have a high level of specificity and are relatively safe. Malignant tumors in the digestive system continue to have a high incidence and mortality rate. Although existing treatment methods have achieved some curative effects, they still require further improvement due to side effects and a lack of specificity. Many studies have shown that oncolytic viruses can kill various tumor cells, including malignant tumors in the digestive system. This review discusses how oncolytic virus therapy improves malignant tumors in the digestive system from the point-of-view of basic and clinical studies. Also, the oncolytic virus anti-tumor mechanisms underpinning the therapeutic potential of oncolytic viruses are expounded. In all, we argue that oncolytic viruses might eventually provide therapeutic solutions to malignant tumors in the digestive system. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Li, Oduro, Guo, Li, Leng, Kong, Wang and Yang.) |
| References: | Mol Ther Oncolytics. 2021 Jun 24;22:388-398. (PMID: 34553027) Mol Ther Oncolytics. 2019 May 13;13:107-115. (PMID: 31193737) Mol Ther Oncolytics. 2021 Oct 30;23:402-411. (PMID: 34853811) Am J Cancer Res. 2018 Aug 01;8(8):1514-1527. (PMID: 30210920) Mol Cancer Res. 2022 Jun 3;20(6):972-982. (PMID: 35190830) Mol Ther Oncolytics. 2020 Apr 08;17:205-215. (PMID: 32346610) Int J Cancer. 2013 Jan 15;132(2):485-94. (PMID: 22729516) J Clin Oncol. 2015 Sep 1;33(25):2780-8. (PMID: 26014293) Oncotarget. 2018 Apr 6;9(26):18041-18052. (PMID: 29719589) J Virol. 2017 Jul 27;91(16):. (PMID: 28566376) Adv Virol. 2012;2012:805629. (PMID: 22400027) Res Vet Sci. 2021 Oct;139:159-165. (PMID: 34332418) Oncotarget. 2017 Apr 11;8(15):24694-24705. (PMID: 28445966) Cancer Med. 2015 Jul;4(7):1051-9. (PMID: 25826750) J Immunother Cancer. 2019 Jan 9;7(1):6. (PMID: 30626434) J Cancer. 2018 Feb 28;9(6):1033-1049. (PMID: 29581783) J Virol. 2018 Nov 12;92(23):. (PMID: 30232179) Nat Rev Cancer. 2016 Mar;16(3):131-44. (PMID: 26911188) Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. (PMID: 29653857) Oncotarget. 2021 Feb 16;12(4):344-354. (PMID: 33659045) Cancers (Basel). 2021 Jul 16;13(14):. (PMID: 34298774) J Immunother Cancer. 2021 Apr;9(4):. (PMID: 33837053) Glycobiology. 2018 Sep 1;28(9):648-655. (PMID: 29272415) Virol J. 2022 Feb 23;19(1):32. (PMID: 35197076) Mol Biol Rep. 2019 Jun;46(3):3371-3379. (PMID: 31006094) Mol Ther Oncolytics. 2019 Jan 25;12:246-258. (PMID: 30891489) Cancer Cell. 2021 Mar 8;39(3):394-406.e4. (PMID: 33482123) Asian Pac J Cancer Prev. 2015;16(3):1241-5. (PMID: 25735362) Trends Mol Med. 2013 Jun;19(6):378-92. (PMID: 23540715) Oncotarget. 2017 Sep 20;8(47):82728-82739. (PMID: 29137298) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Nat Commun. 2020 Mar 13;11(1):1395. (PMID: 32170083) Transl Cancer Res. 2021 Oct;10(10):4290-4302. (PMID: 35116288) Mol Ther. 2020 May 6;28(5):1263-1275. (PMID: 32145202) Cancer Lett. 2017 Jun 28;396:155-166. (PMID: 28315430) Front Oncol. 2020 Mar 24;10:384. (PMID: 32266155) Osong Public Health Res Perspect. 2019 Aug;10(4):246-252. (PMID: 31497497) Cells. 2020 Jan 13;9(1):. (PMID: 31941155) Viruses. 2021 Jun 17;13(6):. (PMID: 34204248) Viruses. 2017 Apr 24;9(4):. (PMID: 28441762) J Virol. 2020 Jan 17;94(3):. (PMID: 31694943) Cancer Gene Ther. 2009 Apr;16(4):291-7. (PMID: 18989355) Viruses. 2021 Sep 03;13(9):. (PMID: 34578339) Nat Rev Immunol. 2015 Jul;15(7):405-14. (PMID: 26027717) Mol Ther Oncolytics. 2019 Mar 27;13:22-34. (PMID: 31011625) Oncotarget. 2017 Apr 20;8(42):71489-71499. (PMID: 29069721) J Am Coll Surg. 2012 Sep;215(3):379-87. (PMID: 22704820) Nanomedicine (Lond). 2022 Mar;17(6):405-421. (PMID: 35118878) Sci Transl Med. 2014 Mar 5;6(226):226ra32. (PMID: 24598590) Cell Death Dis. 2020 Dec 12;11(12):1062. (PMID: 33311488) Cancer Cell Int. 2014 Sep 19;14(1):83. (PMID: 25360068) Oncol Lett. 2021 Jun;21(6):490. (PMID: 33968206) Cancers (Basel). 2020 Apr 25;12(5):. (PMID: 32344903) Mol Ther Oncolytics. 2020 Jun 25;18:262-271. (PMID: 32728614) J Immunother Cancer. 2018 Dec 4;6(1):140. (PMID: 30514385) Oncol Rep. 2021 Feb;45(2):535-546. (PMID: 33416161) Cell Death Differ. 2021 Jan;28(1):68-83. (PMID: 33223522) Front Cell Dev Biol. 2021 Nov 26;9:790150. (PMID: 34901031) Cancers (Basel). 2018 May 25;10(6):. (PMID: 29799479) Mol Ther Oncolytics. 2019 Jul 23;14:266-278. (PMID: 31463367) Cancer Res. 2007 Jan 15;67(2):440-4. (PMID: 17234749) Cell Death Dis. 2020 Jan 22;11(1):48. (PMID: 31969562) Br J Cancer. 2020 Jan;122(1):111-120. (PMID: 31819179) Cancer Commun (Lond). 2018 Aug 3;38(1):52. (PMID: 30075743) FEBS Lett. 2020 Feb;594(4):763-775. (PMID: 31643074) Mol Cancer Ther. 2017 Apr;16(4):662-670. (PMID: 28138026) Lung Cancer. 2014 Nov;86(2):231-6. (PMID: 25236982) Mol Ther Oncolytics. 2020 Jan 11;16:158-171. (PMID: 32055679) Breast Cancer Res Treat. 2016 Apr;156(3):607-608. (PMID: 27026359) Nat Rev Cancer. 2008 Oct;8(10):782-98. (PMID: 18813321) Int J Hyperthermia. 2019;36(1):344-350. (PMID: 30776922) Int J Mol Sci. 2020 Oct 12;21(20):. (PMID: 33053757) Hum Gene Ther. 2021 Feb;32(3-4):216-230. (PMID: 33481658) Cell Mol Life Sci. 2020 May;77(9):1745-1770. (PMID: 31690961) Int J Cancer. 2013 Sep 1;133(5):1107-18. (PMID: 23420584) Anticancer Res. 2018 Nov;38(11):6121-6126. (PMID: 30396927) J Virol. 2003 Sep;77(18):10071-7. (PMID: 12941917) JAMA. 2016 Apr 19;315(15):1600-9. (PMID: 27092830) Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226) Cancer Treat Res Commun. 2021;28:100422. (PMID: 34147821) Clin Cancer Res. 2017 Oct 1;23(19):5846-5857. (PMID: 28536305) Arch Virol. 2020 Mar;165(3):793-797. (PMID: 31980941) JAMA Oncol. 2017 Jun 01;3(6):841-849. (PMID: 27441411) J Immunol. 2018 Apr 15;200(8):2987-2999. (PMID: 29555782) Mol Ther. 2008 Aug;16(8):1382-91. (PMID: 18545226) Mol Ther. 2007 Sep;15(9):1686-93. (PMID: 17579581) Cancer Cell Int. 2020 Nov 2;20(1):532. (PMID: 33292203) Hum Gene Ther. 2018 Nov;29(11):1301-1314. (PMID: 29739251) Mol Ther Oncolytics. 2019 Apr 11;13:82-92. (PMID: 31061881) Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402. (PMID: 32078405) APMIS. 2016 Oct;124(10):896-904. (PMID: 27457663) Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308) J Gen Virol. 2017 Dec;98(12):2895-2911. (PMID: 29143726) Cell. 2017 Sep 7;170(6):1109-1119.e10. (PMID: 28886381) Med Sci Monit. 2000 Sep-Oct;6(5):1047-52. (PMID: 11208453) Cancer Biother Radiopharm. 2006 Jun;21(3):225-34. (PMID: 16918299) World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. (PMID: 30487695) Anticancer Drugs. 2020 Feb;31(2):110-122. (PMID: 31658131) Cancer Gene Ther. 2012 Apr;19(4):229-37. (PMID: 22193629) Front Immunol. 2021 May 18;12:674400. (PMID: 34084172) Clin Cancer Res. 2020 Jan 1;26(1):71-81. (PMID: 31694832) Cells. 2020 Jun 05;9(6):. (PMID: 32516884) Int J Cancer. 2017 Dec 15;141(12):2505-2516. (PMID: 28857157) Viruses. 2021 Sep 24;13(10):. (PMID: 34696348) J Immunother Cancer. 2022 Mar;10(3):. (PMID: 35256516) Exp Ther Med. 2020 Mar;19(3):1997-2007. (PMID: 32104259) Mol Ther Oncolytics. 2020 Aug 21;18:535-545. (PMID: 32995479) Nat Rev Immunol. 2018 Aug;18(8):498-513. (PMID: 29743717) Neoplasma. 2022 Jan;69(1):36-48. (PMID: 34881625) J Am Coll Surg. 2020 Apr;230(4):709-717. (PMID: 32032721) Int J Mol Sci. 2018 Sep 07;19(9):. (PMID: 30205505) Mol Ther. 2018 Apr 4;26(4):1008-1019. (PMID: 29478729) Asian Pac J Cancer Prev. 2019 Oct 01;20(10):3071-3075. (PMID: 31653156) Oncotarget. 2016 Jul 26;7(30):47287-47301. (PMID: 27323824) Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4504-12. (PMID: 25288727) Cancer Immunol Res. 2016 Jun;4(6):531-40. (PMID: 27045021) Clin Cancer Res. 2019 Apr 15;25(8):2392-2402. (PMID: 30463850) Hum Gene Ther. 2021 Feb;32(3-4):203-215. (PMID: 33176492) Oncotarget. 2016 Jan 12;7(2):1500-15. (PMID: 26625205) Nat Rev Clin Oncol. 2019 Jan;16(1):11-26. (PMID: 30341417) Gene. 1992 Dec 15;122(2):281-8. (PMID: 1336756) Mol Ther Oncolytics. 2020 Mar 31;17:107-117. (PMID: 32322667) BMC Cancer. 2018 May 25;18(1):596. (PMID: 29801474) Sci Transl Med. 2020 Jan 15;12(526):. (PMID: 31941828) Cell Biosci. 2021 Sep 20;11(1):174. (PMID: 34544479) Cancer Lett. 2021 Apr 1;502:9-24. (PMID: 33444691) Front Pharmacol. 2021 Oct 15;12:735278. (PMID: 34721024) Int J Mol Sci. 2020 Sep 25;21(19):. (PMID: 32992948) Mol Ther Oncolytics. 2020 Nov 17;20:71-81. (PMID: 33575472) |
| فهرسة مساهمة: | Keywords: cancer; digestive system; immunotherapy; oncolytic virus; tumor |
| المشرفين على المادة: | 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20220620 Date Completed: 20220621 Latest Revision: 20220817 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9203847 |
| DOI: | 10.3389/fcimb.2022.921534 |
| PMID: | 35719333 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-2988 |
|---|---|
| DOI: | 10.3389/fcimb.2022.921534 |